Collegium Pharmaceutical (COLL) Share-based Compensation (2014 - 2026)

Collegium Pharmaceutical's Share-based Compensation history runs 13 years deep, the most recent figure standing at $15.4 million for Q1 2026.

• On a quarterly basis, Share-based Compensation rose 45.69% year-over-year to $15.4 million in Q1 2026; TTM through Mar 2026 was $69.5 million, a 24.06% increase from a year earlier, with the FY2025 full-year figure at $41.9 million, up 29.34% from the prior year.
• Share-based Compensation declined to $15.4 million in Q1 2026 per COLL's latest filing, from $29.9 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $76.7 million in Q2 2025 and bottomed at -$13.2 million in Q4 2022.
• The 5-year median for Share-based Compensation is $12.9 million (2024), against an average of $22.1 million.
• Across the five-year window, Share-based Compensation sank 367.92% in 2022 and soared 670.81% in 2024, its largest moves.
• Year by year, Share-based Compensation stood at -$13.2 million in 2022, then surged by 244.44% to $19.0 million in 2023, then decreased by 28.93% to $13.5 million in 2024, then surged by 121.49% to $29.9 million in 2025, then tumbled by 48.42% to $15.4 million in 2026.
• Per Business Quant, the three latest COLL Share-based Compensation figures stand at $15.4 million (Q1 2026), $29.9 million (Q4 2025), and $66.2 million (Q3 2025).